U.S. markets open in 3 hours 8 minutes

Anebulo Pharmaceuticals, Inc. (ANEB)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
7.26+0.14 (+1.94%)
At close: 12:04PM EDT

Anebulo Pharmaceuticals, Inc.

1415 Ranch Road 629 South
Suite 201
Lakeway, TX 78734
United States

Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Dr. Joseph F. LawlerFounder & ChairmanN/AN/A1973
Dr. Daniel Schneeberger M.B.A., M.D.CEO & DirectorN/AN/A1985
Mr. Rex Merchant CFAChief Financial OfficerN/AN/A1960
Dr. Linda Klumpers Ph.D.Chief Scientific OfficerN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing treatments for patients suffering from cannabinoid overdose and addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.

Corporate Governance

Anebulo Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.